Razi's four vaccine products Technology and future output

Date unknown

The Marand report says Razi's northwestern branch developed technology for four new livestock/poultry products and has annual capacity around four hundred million biological-product doses. Razzagh Hosseinpour recalls its history; Mehdi Radmehri praises personnel and equipment, and Rahim Ghadimipour describes testing with European positive controls. Hosseinpour outlines planned avian-influenza formulations and a genotype-seven Newcastle vaccine. The report expects flock protection and supply resilience after market entry. Quality and self-sufficiency claims remain attributed; future production and market availability are not completed commercial launches.

Razi's northwestern Marand branch reports technology development for four new livestock/poultry products, including avian-influenza formulations and a genotype-seven Newcastle vaccine. Officials describe development, testing and planned production and expect improved protection and supply resilience. The report does not establish commercial release of all four products.